Emerging Trials in the Management of HR+/HER2- Locally Advanced or Metastatic Breast Cancer
July 16th 2024Adam M. Brufsky, MD, PhD, and Erika P. Hamilton, MD, share their perspectives on the future landscape of HR+/HER2- locally advanced or metastatic breast cancer treatment and provide essential insights to summarize the key points of their discussion.
Read More
Targeted Therapies in HR+/HER2- Locally Advanced or Metastatic Breast Cancer: CAPItello-291
July 9th 2024Erika P. Hamilton, MD, discusses the CAPItello-291 trial, which investigated the combination of capivasertib and fulvestrant in advanced HR+, HER2- locally advanced or metastatic breast cancer and led to its FDA approval, emphasizing the improved progression-free survival observed in patients with PIK3CA, AKT1, and PTEN alterations.
Read More
Mechanisms of Resistance after 1L CDK4/6i + ET: The PI3K/AKT/PTEN Pathway
July 2nd 2024Key opinion leaders explore the mechanisms of resistance that can develop after endocrine therapy and CDK4/6 inhibitor treatment in HR+/HER2- locally advanced or metastatic breast cancer, emphasizing the uncertain etiology of resistance and current hypotheses, while also examining biomarkers that may predict resistance to CDK4/6 inhibitors and endocrine therapy.
Read More
Biomarker Testing Best Practices in HR+/HER2- Locally Advanced or Metastatic Breast Cancer
June 26th 2024Adam M. Brufsky, MD, PhD, and Erika P. Hamilton, MD, delve into the most clinically significant genomic tests and biomarker assays employed in HR+/HER2- breast cancer, focusing on BRCA mutations, PIK3CA alterations, AKT1 alterations, and PTEN alterations, which play crucial roles in determining prognosis and guiding treatment decisions.
Read More
Medical experts share their strategies for choosing initial treatment options for HR+/HER2- locally advanced or metastatic breast cancer, debating the most effective frontline therapies based on clinical trial evidence, while also discussing their aspirations for a new standard of care, and the challenges of managing disease progression.
Read More
Dr Hamilton on the Investigation of HER3-DXd in ER+ Breast Cancer and TNBC
June 23rd 2023Erika P. Hamilton, MD, discusses the investigation of patritumab deruxtecan in heavily pretreated patients with metastatic estrogen receptor-positive or triple-negative breast cancer with varying levels of HER3 expression in a phase 2 trial.
Read More
Dr. Hamilton on Trastuzumab Deruxtecan in HER2+ Breast Cancer
November 28th 2022Erika P. Hamilton, MD, discusses previously reported and anticipated findings from the DESTINY-Breast03 trial, which compared the efficacy of 2 antibody-drug conjugates, fam-trastuzumab deruxtecan-nxki and ado-trastuzumab emtansine, in patients with HER2-positive metastatic breast cancer.
Read More
Dr. Hamilton on the Results of the nextMONARCH Trial in Patients With HR+/HER2- Breast Cancer
September 23rd 2020Erika P. Hamilton, MD, discusses the final overall survival results from the randomized, phase 2 nextMONARCH trial in patients with hormone receptor–positive, HER2-negative metastatic breast cancer.
Read More